Skip to content

Pharmacology & Therapeutics

ISSN 1879-016X, 0163-7258

16 papers in the library · 1,828 citations · publishing 2003-2024

Papers

Sort Most recent Most cited

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases

Pharmacology & Therapeutics April 6, 2024 Zarah R. Haniff, Mariia Bocharova, Tim Mantingh et al. 16 citations

Major depression is an established risk factor for subsequent dementia, and depression in late life may also represent a prodromal state of dementia. Considering current challenges in the clinical development of disease modifying therapies for dementia, the focus of research is shifting towards prevention and modification of risk factors to alter the neurodegenerative disease trajectory....

Potential neonatal toxicity of new psychoactive substances.

Pharmacology & Therapeutics August 1, 2023 Ryoichi Fujiwara, Megan Journey, Fatimah Al-Doori et al. 13 citations

Cannabis, cocaine, 3,4-methylenedioxymethamphetamine, and lysergic acid diethylamide are psychoactive substances with a significant increase in consumption during the 21st century due to their popularity in medicinal and recreational use. New psychoactive substances (NPSs) mimic established psychoactive substances. NPSs are known as being natural and safe to consumers; however, they are neither...

The Antidepressant Actions of Ketamine and its Enantiomers

Pharmacology & Therapeutics May 1, 2023 J. Johnston, Ioline D. Henter, Carlos A. Zarate 106 citations

Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist first developed as an anesthetic, has shown significant promise as a medication with rapid antidepressant properties in treatment-resistant depression. However, concerns such as adverse side effects and potential misuse liability have limited its widespread use. Racemic ketamine has two enantiomers—(S)- and (R)-ketamine—that appear...

Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.

Pharmacology & Therapeutics November 1, 2022 Sanket B Raut, Padmaja A Marathe, Liza Van Eijk et al. 62 citations

Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options. Current treatment guidelines recommend psychotherapy as first line management with only two drugs, sertraline and paroxetine, approved by U.S. Food and Drug Administration (FDA) for treatment of PTSD. These drugs have...

Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.

Pharmacology & Therapeutics July 1, 2019 T. H. Pham, Alain M. Gardier 190 citations

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays a fast antidepressant activity in treatment-resistant depression and in rodent models of anxiety/depression. A large body of evidence concerning the cellular and molecular mechanisms underlying its fast antidepressant-like activity comes from animal studies. Although structural remodeling of...

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Pharmacology & Therapeutics May 1, 2019 Matthew W Johnson, Peter S. Hendricks, Frederick S. Barrett et al. 520 citations

The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times. They were of prominent interest...

The neuropsychopharmacology of cannabis: A review of human imaging studies

Pharmacology & Therapeutics October 20, 2018 Michael Bloomfield, Chandni Hindocha, Sebastian F Green et al. 236 citations

receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of...

The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

Pharmacology & Therapeutics October 2018 Chadi G. Abdallah, Gerard Sanacora, Ronald S. Duman et al.

The discovery of the antidepressant effects of ketamine has opened a breakthrough opportunity to develop a truly novel class of safe, effective, and rapid-acting antidepressants (RAADs). In addition, the rapid and robust biological and behavioral effects of ketamine offered a unique opportunity to utilize the drug as a tool to thoroughly investigate the neurobiology of stress and depression in...

Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?

Pharmacology & Therapeutics February 1, 2018 Laura Hondebrink, Anne Zwartsen, Remco H S Westerink 78 citations

The use of new psychoactive substances (NPS) is increasing and currently >600 NPS have been reported. However, limited information on neuropharmacological and toxicological effects of NPS is available, hampering risk characterization. We reviewed the literature on the in vitro neuronal modes of action to obtain effect fingerprints of different classes of illicit drugs and NPS. The most...

DOI: 10.1016/j.pharmthera.2017.10.022 (opens in new tab) Full text (opens in new tab) Designer drugs Mechanism of action Receptors Transporters +5

Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders.

Pharmacology & Therapeutics March 1, 2016 Linda Nguyen, Kelan Thomas, Brandon P Lucke-Wold et al.

Dextromethorphan (DM) is a commonly used antitussive and is currently the only FDA-approved pharmaceutical treatment for pseudobulbar affect. Its safety profile and diverse pharmacologic actions in the central nervous system have stimulated new interest for repurposing it. Numerous preclinical investigations and many open-label or blinded clinical studies have demonstrated its beneficial...

Ketamine and the next generation of antidepressants with a rapid onset of action

Pharmacology & Therapeutics May 3, 2009 Rodrigo Machado‐Vieira, Giacomo Salvadore, Nancy Diazgranados et al.

Existing treatments for major depressive disorder (MDD) usually take weeks to months to achieve their antidepressant effects, and a significant number of patients do not have adequate improvement even after months of treatment. In addition, increased risk of suicide attempts is a major public health concern during the first month of standard antidepressant therapy. Thus, improved therapeutics...

Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.

Pharmacology & Therapeutics May 1, 2004 Dennis J. Mckenna 299 citations

Ayahuasca is a hallucinogenic beverage that is prominent in the ethnomedicine and shamanism of indigenous Amazonian tribes. Its unique pharmacology depends on the oral activity of the hallucinogen, N,N-dimethyltryptamine (DMT), which results from inhibition of monoamine oxidase (MAO) by beta-carboline alkaloids. MAO is the enzyme that normally degrades DMT in the liver and gut. Ayahuasca has...

Hallucinogens and dissociative agents naturally growing in the United States.

Pharmacology & Therapeutics May 1, 2004 John H. Halpern 209 citations

It is usually believed that drugs of abuse are smuggled into the United States or are clandestinely produced for illicit distribution. Less well known is that many hallucinogens and dissociative agents can be obtained from plants and fungi growing wild or in gardens. Some of these botanical sources can be located throughout the United States; others have a more narrow distribution. This article...

DOI: 10.1016/j.pharmthera.2004.03.003 (opens in new tab) Full text (opens in new tab) Ayahuasca Natural hallucinogens Psychedelic plants Entheogenic fungi +23

Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery.

Pharmacology & Therapeutics May 1, 2004 Bryan L. Roth, Estela Lopez, Scott Beischel et al. 98 citations

Because psychoactive plants exert profound effects on human perception, emotion, and cognition, discovering the molecular mechanisms responsible for psychoactive plant actions will likely yield insights into the molecular underpinnings of human consciousness. Additionally, it is likely that elucidation of the molecular targets responsible for psychoactive drug actions will yield validated...

DOI: 10.1016/j.pharmthera.2004.03.004 (opens in new tab) Full text (opens in new tab) Cns drug discovery Neuroscience drug discovery Psychopharmacology Neurotherapeutics +16

Hallucinogens.

Pharmacology & Therapeutics February 1, 2004 David E Nichols 1 citation

Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes. They are considered physiologically safe and do not produce dependence or addiction. Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts. In the 1950s, after the virtually contemporaneous...

Altered states: the clinical effects of Ecstasy.

Pharmacology & Therapeutics April 2003 J C Cole, Harry Sumnall

Ecstasy is the second most widely abused illegal drug in Europe. Ecstasy is the colloquial name for 3,4-methylenedioxymethamphetamine (MDMA), but not all Ecstasy tablets contain MDMA. When taken in hot, crowded environments, Ecstasy/MDMA users have developed acute complications that have had fatal consequences. Epidemiological evidence indicates that adverse reactions to Ecstasy/MDMA...